BBIO · XBRL financial data

BridgeBio Pharma financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BBIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	8	70	78	9	222	502
Cost of revenue	—	3	3	2	4	21
Cost of goods and services sold	—	3	—	—	—	—
Research and development	337	451	399	456	506	452
Selling, general and administrative	146	192	143	151	289	531
General and administrative	146	—	—	—	—	—
Total operating expenses	483	—	—	—	—	—
Operating income (loss)	(474)	(577)	(512)	(607)	(593)	(523)
Interest income	4	1	8	18	17	20
Interest expense	37	47	80	81	99	53
Other income (expense)	2	36	(8)	17	12	43
Income tax expense (benefit)	—	—	0	0	1	0
Earnings per share, basic USD per share	(3.80)	(3.90)	(3.26)	(3.95)	(2.88)	(3.78)
Earnings per share, diluted USD per share	(3.80)	(3.90)	(3.26)	(3.95)	(2.88)	(3.78)
Weighted average shares, basic millions of shares	118	144	147	163	186	192
Weighted average shares, diluted millions of shares	118	144	147	163	186	192

Fiscal years (BBIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	356	394	377	376	681	570
Marketable securities	251	394	52	0	0	17
Accounts receivable	—	—	—	2	5	139
Inventory	—	—	—	—	0	27
Prepaid and other current assets	36	32	22	24	35	44
Total current assets	643	889	549	478	721	798
Property and equipment, net	20	30	15	12	7	5
Right-of-use asset	17	16	11	8	6	8
Total assets	704	1,013	623	546	919	936
Accounts payable	9	12	12	11	10	36
Current portion of long-term debt	1	—	—	—	—	—
Total current liabilities	96	135	121	144	154	288
Long-term debt	92	431	431	446	437	—
Lease liability, non-current	15	17	12	9	5	4
Total liabilities	596	1,878	1,868	1,889	2,377	3,013
Accumulated deficit	(889)	(1,437)	(1,918)	(2,561)	(3,096)	(3,821)
Total stockholders' equity	58	(870)	(1,255)	(1,354)	(1,468)	(2,087)
Total liabilities and equity	704	1,013	623	546	919	936
Common shares outstanding (cover page) millions of shares	149	148	151	176	190	194

Fiscal years (BBIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Stock-based compensation	58	100	92	109	96	133
Depreciation and amortization	1	6	7	6	6	5
Net cash from operating activities	(400)	(498)	(419)	(528)	(521)	(446)
Purchases of property and equipment	8	13	5	1	1	1
Net cash from investing activities	(53)	(201)	453	54	61	(24)
Proceeds from issuing common stock	0	0	5	144	315	0
Share repurchases	75	200	0	0	0	48
Repayments of long-term debt	0	124	20	0	473	—
Net cash from financing activities	447	736	(13)	452	748	359
Net change in cash	(6)	38	21	(22)	289	(111)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
BridgeBio Pharma	1,533	353	(44)*	194.8M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.